Spravato Ketamine Depression Study
Purpose
The purpose of this study is to evaluate the efficacy, safety, and tolerability of an investigational medication, (SPRAVATOTM)
Study Summary
A clinical trial for Esketamine Nasal Spray, SPRAVATOTM, as a standalone therapy for adult participants with treatment-resistant depression (TRD). Esketamine nasal spray (SPRAVATOTM) is currently approved in the United States for use with an oral antidepressant for the treatment of TRD in adults.
COMPASS
Purpose
This study was created to assess the safety and efficacy of a synthetic analogue of psilocybin for treatment-resistant depression. (Study Summary) This is a phase 3 multisite, active placebo, randomized, double-blind study. Participants will be enrolled for up to 62 weeks and will receive 2-4 dosing of 3 possible sizes of COMP360. Dosing is accompanied by psychotherapy.
Interventional Psychiatry Registry
Purpose
To better understand the long-term effects of novel clinical interventions for mood disorders (ketamine, ECT, TMS, etc.), including durability of treatment efficacy and potential long-term adverse events. (Study Summary) We are establishing a registry of individuals who receive IV ketamine infusions, TMS, ECT, and/or novel clinical treatments, and/or participate in clinical treatment trials for mood disorders to track their treatment progression and psychiatric symptoms over the span of one year.